AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...

Find insight on Regis Healthcare, CSPC Pharmaceutical and more in the latest Market Talks covering the health care sector.

CSPC will use its artificial-intelligence-driven, dual-engine efficient drug discovery platform to analyze the binding ...

The collaboration will focus on identifying pre-clinical candidates for high-priority targets, including a small molecule ...

The deal with China’s CSPC Pharmaceuticals, focused on AI-driven research, aims to advance the discovery and development of ...

Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value ...

Friday’s deal with fits neatly within AstraZeneca’s business development strategy of upping investments in AI and in China.

The collaboration aims to advance the discovery and development of novel oral candidates.

AstraZeneca has signed a research agreement worth more than US$5 billion with Chinese drugmaker CSPC Pharmaceutical Group, ...

AstraZeneca has joined the long list of big pharma companies enlisting the services of Chinese biotechs, signing a deal worth ...

AstraZeneca will pay CSPC upfront fee of $110 million Additional potential payments of up to $5.22 billion to CSPC Deal latest of AstraZeneca efforts to bolster China business, AI The deal marks ...